Back to Journals » Biologics: Targets and Therapy » Volume 2 » Issue 3

Therapeutic options in the management of acromegaly: focus on lanreotide Autogel®

Authors Roelfsema F, Biermasz NR, Pereira AM, Romijn JA

Published 12 September 2008 Volume 2008:2(3) Pages 463—479

DOI https://doi.org/10.2147/BTT.S3356

Review by Single-blind

Peer reviewer comments 3

Ferdinand Roelfsema, Nienke R Biermasz, Alberto M Pereira, Johannes A Romijn

Department of Endocrinology and Metabolism, Leiden University Medical Center, Leiden, The Netherlands

Background: In acromegaly, expert surgery is curative in only about 60% of patients. Postoperative radiation therapy is associated with a high incidence of hypopituitarism and its effect on growth hormone (GH) production is slow, so that adjuvant medical treatment becomes of importance in the management of many patients.

Objective: To delineate the role of lanreotide in the treatment of acromegaly.

Methods: Search of Medline, Embase, and Web of Science databases for clinical studies of lanreotide in acromegaly.

Results: Treatment with lanreotide slow release and lanreotide Autogel® normalized GH and insulin-like growth factor-I (IGF-I) concentrations in about 50% of patients. The efficacy of 120 mg lanreotide Autogel® on GH and IGF-I levels was comparable with that of 20 mg octreotide LAR. There were no differences in improvement of cardiac function, decrease in pancreatic β-cell function, or occurrence of side effects, including cholelithiasis, between octreotide LAR and lanreotide Autogel®. When postoperative treatment with somatostatin analogs does not result in normalization of serum IGF-I and GH levels after noncurative surgery, pegvisomant alone or in combination with somatostatin analogs can control these levels in a substantial number of patients.

Keywords: acromegaly, lanreotide, somatostatin analog, growth hormone, pegvisomant

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]